Spectral AI Inc (MDAI)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
$1.57+0.64%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Spectral AI aims to generate its first commercial sales of the DeepView System by end of 2026. The company forecasts revenue of $18.5 million for 2026, up from $3.99 million in Q1. New CEO and CFO bring positive leadership changes. FDA clearance has improved market sentiment.
The company is loss-making and revenue growth is uncertain. Recent sharp stock selloff shows investor concern. Revenue forecast requires significant growth in remaining quarters, which is not yet evident.
The price is about 28% below our fair value of $2.47. Analysts expect about 24% revenue growth, which is roughly in line with the company's $18.5 million 2026 revenue forecast. Our view is cautious given the company's losses and volatile management.
Breaks if: No commercial sales of DeepView System by end of 2026
Breaks if: Additional key executive departures occur within next 12 months
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. MDAI is in a critical phase as it aims to generate its first commercial sales while facing weak recent financial performance and high risk.
The current valuation reflects a justified premium compared to peers, with the market expecting some stabilization in revenue. However, there is a notable expectations gap, indicating that the market may not fully account for potential challenges ahead.
Fundamentals are likely to remain weak in the near term, as revenue has declined quarter-over-quarter. The company's focus on commercial sales of the DeepView System is a key priority, but it has not yet shown material impact on revenue.
The long-term thesis hinges on MDAI's ability to successfully launch the DeepView System and generate sales by the end of 2026. Additionally, external factors such as sector performance and economic conditions will play a significant role in shaping the company's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue for FY26 falls below $18.5 million
Over the next 1 to 3 years, MDAI's performance will depend on its execution of commercial strategies and broader market conditions. Not investment advice.